NCT01003938View on ClinicalTrials.gov

Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

September 30, 2012

Study Completion Date

December 31, 2012

Conditions
Ovarian Cancer
Interventions
DRUG

Topotecan

DRUG

Erlotinib

Trial Locations (3)

10016

Bellevue Hospital Center, New York

NYU Clinical Cancer Center, New York

Tisch Hospital, New York

Sponsors

Collaborators (1)

OSI Pharmaceuticals
All Listed Sponsors
collaborator

OSI Pharmaceuticals

INDUSTRY

lead

NYU Langone Health

OTHER